India, Feb. 26 -- India's biologics and biosimilars market is entering a decisive growth phase, and the opportunity is both immediate and transformative. With several global biologics going off patent, rising demand for affordable therapies, and strong government backing through initiatives such as Biopharma Shakti, Manoj Kumar R Panicker, General Manager - South Asia, Cytiva believes India is positioned to become a major global hub for biologics development and manufacturing.

Panicker, who transitioned from a mechanical engineering background into life sciences innovation and holds 12 international patents, says the convergence of engineering excellence and bioprocess innovation is unlocking new commercial possibilities. "India already ...